

**Welcome to the 2019
AFDO Cannabis Committee**

Claudia Coles & Travis Waller – Co-Chairs

Cannabis Committee Agenda

- Edible Cannabis Products: Analysis of current best practices in the U.S.
 - Aurash Jason Soroosh, Maryland Department of Health
- Update on Cannabis & Hemp Bill in 2019
 - Doug Farquhar, J.D., National Conference for State Legislatures
- ASTM International Cannabis Standard
 - Lezli Engelking, FOCUS: The Cannabis Health & Safety Organization

CERTIFIED PURE CBD BLEND

Feel Great

HEMP BOMBS™

Relax Now



CBD GUMMIES

GROCERY
\$6.99

5 MAX STRENGTH GUMMIES



HIGHER POTENCY 75



Benefits May Include:

- Pain Relief
- Combats Anxiety
- Healthy Lifestyle
- Natural Sleep
- Reduce Stress
- Relaxing Calm

COMPLETE RELAXATION

Hydrate

“Excellent product. Tastes as it should, meaning tastes like water. Product doesn’t have or leave any unpleasant aftertaste after drinking. Used after exercising and found a nice feeling of hydration and satisfaction after thirst. ” – Aloha Patrick, Hemp H2O Customer

Recovery & Relaxation

“I really enjoy taking PlusCBD Oil™ hemp-derived products on a daily basis. Whether I’m on the go, or it’s late at night, PlusCBD Oil™ has a wide variety of full spectrum hemp extracts in strengths and delivery methods I can choose based on my mood. It’s also great that PlusCBD Oil™ products provide the health benefits of CBD, plant sterols, terpenes, chlorophyll and naturally occurring Vitamin E.”

– Jessica, PlusCBD Oil™ Customer

Other brands for muscle recovery and inflammation: Shikai, Medterra, Veritas, Select, Sagely Naturals, Oleo

Pet Care

“After the vet said Bailey had arthritis, we started using CBD to help ease his inflammation and pain. Plus it’s free from wheat, corn, soy, preservatives and artificial ingredients. An added bonus – we love that it’s locally-produced in Seattle.” – Brandon, Bartell’s Customer

<https://www.bartelldrugs.com/products/cbd/>

FDA Announcements

The FDA is extending the comment period for the notice that appeared in the Federal Register of April 3, 2019. The notice announced a public hearing to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds. In addition, it notified the public that FDA was establishing a docket for public comment on this hearing and that the docket would close on July 2, 2019. We are extending the comment period to give interested parties more time to comment.

July 16, 2019 is the new deadline.

FDA Announcements - FDA Voices

- Science forms the basis for decisions at the FDA and is paramount when it comes to making decisions that will impact the health and safety of the American public. We apply this rigorous, science-based approach to matters large and small that come before the Agency — including with respect to products containing cannabis or cannabis-derived compounds, including cannabidiol (CBD).
- We recognize that there is significant public interest in these products, for therapeutic purposes and otherwise. At the same time, there are many unanswered questions about the science, safety, and quality of many of these products. As we approach these questions, we do so as a science-based regulatory agency committed to our mission of protecting and promoting public health.

FDA Consumer Updates

You may have noticed that cannabidiol (CBD) seems to be available almost everywhere, and marketed as a variety of products including drugs, food, dietary supplements, cosmetics, pet food, and other animal health products.

The FDA recognizes the significant public interest in cannabis and cannabis-derived compounds, particularly CBD. However, there are many unanswered questions about the science, safety, and quality of products containing CBD. The Agency is working on answering these questions through ongoing efforts including feedback from a recent [FDA hearing](#) and information and data gathering through a [public docket](#) that is open for comment until [July 16, 2019](#).

The FDA [Stakeholder Engagement Staff](#) reside within the Office of the Commissioner and support the FDA mission by engaging with Patient and Health Professional Organizations, Consumer Groups, Trade Associations, Think Tanks and other external stakeholders. We encourage and support active engagement from external

Presentations

